Welcome to DrugsInTheMaking.Com
Quetiapine Associated With More Rapid Onset Of Metabolic Disturbances In Elderly Patients. 08/24/2010
 Dr.Shruti Bhat, Star formulator and Ace leader within pharmaceutical R&D, a specialist with hiTech formulations and quality-by-design. Shruti brings to you some highlights from current pharma and clinical research news, views and data. Misoprostol May Be As Effective As Oxytocin In Speeding Labor For Women With Inadequate Contractions. "Titrated oral doses of misoprostol (Cytotec) may be as effective as intravenous oxytocin in speeding labor in women who have inadequate contractions, according to" a study published in J. Obstetrics & Gynecology. Taiwanese researchers found that in "a randomized trial of more than 200 Chinese women, the median times from treatment to vaginal delivery were ... Trastuzumab May Help Extend Stomach Cancer Patients' Survival By Nearly Three Months. Patients with HER2-positive advanced gastric cancer might benefit from a drug produced by Roche Holding AG. “Use of the drug trastuzumab in addition to chemotherapy can extend stomach cancer patients' survival by nearly three months," researchers in Seoul found after evaluating "584 patients at 122 centers in 24" nations. The "addition of trastuzumab to standard cisplatin/fluoropyrimidine chemotherapy resulted in a median survival of ... Breast Cancer Drug Fulvestrant Appears More Effective In The Presence Of CK8 And CK18. Women’s responsiveness to the second-line breast cancer drug fulvestrant may depend on whether the cancer cells are expressing two key proteins, Indiana University Bloomington scientists report in this month’s Cancer Biology & Therapy. Fulvestrant appeared to exert maximum anti-cancer effects in vitro when cells produced normal or ... Eprotirome May Lower Cholesterol Levels Without Feared Side Effects Of Thyroid-Based Drugs. "A thyroid-derived cholesterol-lowering drug," called eprotirome, "that could be an alternative to the widely used statin medications has done well in a small, early trial, Swedish and American researchers report." For the 12-week trial, various doses of eprotirome "were added to statin treatment for 168 people whose high levels of LDL cholesterol ... Third Study Shows Bisphosphonates May Cut Risk Of Breast Cancer. According to a study appearing in the British Journal of Cancer, researchers "found a reduction in the risk for breast cancer among postmenopausal women taking bisphosphonates for the treatment of osteoporosis." The study showed that ... Intravitreous Dexamethasone Effective Treatment For DME. According to a study published in the Archives of Ophthalmology, "intravitreous treatment with dexamethasone is well tolerated and significantly improves visual acuity in patients with persistent diabetic macular edema (DME)." In a trial in which 315 DME patients were ... Anti-TNF Therapy For Psoriatic Arthritis May Improve Physical Disability, Quality Of Life. According to a study published in the March issue of Arthritis Care & Research, "treatment with anti-tumor necrosis factor (TNF) agents can significantly improve physical disability and quality of life for patients with psoriatic arthritis." In a study of 596 patients, researchers found that ... Combination Therapy For Some Alzheimer's Patients May Help Ease Caregiver Distress. According to research presented at a geriatric psychiatry meeting, "caregiver distress is significantly attenuated when patients with moderate to severe Alzheimer's disease (AD) are treated with a combination of extended-release memantine plus a ... Quetiapine Associated With More Rapid Onset Of Metabolic Disturbances In Elderly Patients. According to a study presented at a geriatric psychiatry meeting, "the antipsychotic quetiapine (Seroquel, AstraZeneca) is associated with a more rapid onset of metabolic disturbances than other antipsychotics in elderly patients with no baseline metabolic abnormalities before treatment initiation... References: http://www.medscape.com/viewarticle/718261 http://www.medpagetoday.com/OBGYN/Pregnancy/21833 http://online.wsj.com/article/BT-CO-20100819-715016.html http://consumer.healthday.com/Article.asp?AID=642267 http://www.guardian.co.uk/society/2010/aug/20/price-cancer-drug-herceptin http://newsinfo.iu.edu/news/page/normal/13738.html Disclaimer- The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances. Http://www.drshrutibhat.com Expert at leading Pharmaceutical R&D. Translates innovative concepts to PROFITS. YouTube Channel : Http://www.youtube.com/user/ShrutiBhat10 Introducing ! A new blog- Http://www.PharmaceuticalCareerDevelopment.blogspot.com which contains articles on motivation, career counselling and coaching, job search strategies, personal branding etc. especially for pharma professionals. Do you have questions for the author? Add Comment  Dr.Shruti Bhat, Star formulator and Ace leader within pharmaceutical R&D, a specialist with hiTech formulations and quality-by-design. Shruti brings to you some highlights from current pharma and clinical research news, views and data. FDA Approves First-Ever Human Test Of Embryonic Stem Cell-Based Therapy. The USFDA has approved "the world's first authorized test in people of a therapy derived from human embryonic stem cells." The clinical trial "could offer the first glimpse of the safety and possible effectiveness of a technology that has been hailed for its vast medical promise but also embroiled in political and ethical controversy." The trial ... Scientists Create New Family Of "Super-Antibotics." A new family of "'super-antibotics' capable of beating MRSA (Methicillin resistant Staph. aureus) and other deadly infections” reports a study published in the journal ‘Nature’. In tests, one of the drugs killed strains of the hospital superbug resistant to antibiotics already in use. Others were ... New Antibiotic Designed To Circumvent Drug Resistance. GlaxoSmithKline Plc, the UK's biggest drugmaker, said it has come up with a new antibiotic designed to circumvent the drug resistance that makes many hospital-acquired infections difficult to treat." Glaxo's new compound "latches onto topoisomerase, which helps ... Misoprostol May Revolutionize Abortion Around The World. Researchers are finding an alternative" to abortions "that is safe, cheap, and very difficult for governments to restrict -- misoprostol." Misoprostol "pills are beginning to revolutionize abortion around ... More at ...http://www.pharm-education.com/2010/08/scientists-create-new-family-of-super.html Disclaimer- The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances. Http://www.drshrutibhat.comExpert at leading Pharmaceutical R&D. Translates innovative concepts to PROFITS. YouTube Channel : Http://www.youtube.com/user/ShrutiBhat10 FDA Adds Boxed Warning To Plavix. 07/28/2010
 Dr.Shruti Bhat, Star formulator and Ace leader within pharmaceutical R&D, a specialist with hiTech formulations and quality-by-design. Shruti brings to you some highlights from current pharma and clinical research news, views and data. FDA Adds Boxed Warning To Plavix. FDA "is adding its strongest warning to the label for Plavix [clopidogrel bisulfate], cautioning that some patients do not respond to the blockbuster blood thinner." The "warning indicates ... Canada Approves Seasonal Flu Nasal Vaccine. Health Canada for the first time "granted approval for a nasal vaccine FluMist, designed to protect against seasonal flu." The nasal vaccine which is marketed by AstraZeneca Canada, is ... Extended Stroke Treatment Window Appears To Be A Safe Option For Saving Lives. Extending the time window to treat stroke patients with the clot-dissolving drug tPA from three hours to up to 4.5 hours after the onset of stroke doesn't result in any significant delays in treatment and appears to be a safe option for saving lives," according to a new paper in The Lancet Neurology. ... Reovirus May Hold Promise As Nontoxic Prostate Cancer Treatment. The respiratory, enteric, orphan virus, or 'reovirus' is widespread," but those who are exposed to it tend to "suffer, at most, mild flu-like respiratory symptoms or diarrhea." More interestingly, ... Research Team Finds Q Fever Demands 18 Months Or More Of Treatment. Researchers based in France have outlined treatment for Q fever, and "the findings have relevance because of the current -- and unusual -- outbreak of Q fever in the Netherlands, where 3,483 cases have been diagnosed ... Read more at http://www.pharm-education.com/2010/07/extended-stroke-treatment-window.html Disclaimer- The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances. Http://www.drshrutibhat.com Expert at leading Pharmaceutical R&D. Translates innovative concepts to PROFITS. YouTube Channel : Http://www.youtube.com/user/ShrutiBhat10 Do you have questions for the author?  Dr.Shruti Bhat, Star formulator and Ace leader within pharmaceutical R&D, a specialist with hiTech formulations and quality-by-design. Shruti brings to you some highlights from current pharma and clinical research news, views and data. AIDS Vaginal Gel Considered Promising, But More Work Remains. The best AIDS-prevention news in years was released...last week at a world conference on the disease: a vaginal gel, called a microbicide, that ... FDA Approves Three-In-One Blood Pressure Drug. Daiichi Sankyo Inc. stated that regulators have approved the sale of its three-in-one high blood pressure drug Tribenzor [hydrochlorothiazide, amlodipine, olmesartan medoxomil]." The drug product is intended "to treat patients whose blood pressure is not controlled on angiotensin receptor blockers, calcium channel blockers, or diuretics." The FDA issued ... New "Smart Bomb" invented to target cancer cells. A team of researchers from Australia and India are hard at work developing a new "smart bomb" to target tumors. The investigators are developing an antibody that binds to cancer stem cells, delivering a lipid particle containing an anti-cancer therapy ... Read more: http://www.pharm-education.com/2010/07/new-smart-bomb-tech-used-to-target.html Disclaimer- The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances. Http://www.drshrutibhat.com Expert at leading Pharmaceutical R&D. Translates innovative concepts to PROFITS. YouTube Channel : Http://www.youtube.com/user/ShrutiBhat10  Dr.Shruti Bhat, Star formulator and Ace leader within pharmaceutical R&D, a specialist with hiTech formulations and quality-by-design. Shruti brings to you some highlights from current pharma and clinical research news, views and data. Glaxo R&D changes R&D model : Group Aims To Develop Drugs Like Small Biotech Companies. The Wall Street Journal reported that GlaxoSmithKline has turned its research and development group into a number of specialized teams that aim to discover drugs in a similar way to biotechnology companies. The teams, known as discovery performance units, or DPUs, are about halfway through the three-year budgets they were given in 2008, and the company has notified them that if they don't produce, there will be layoffs. The company has also reduced its R&D staff by about 20% since 2006, and increased its investment in outside research firms. http://online.wsj.com/article/SB10001424052748704569204575328580921136768.html.html Europeans Said To Be Skeptical Of Flu Vaccines. The Financial Times reported that Europeans are skeptical of flu vaccines. Thus, drug companies predict, there will be no increase in demand for the vaccines across the European Union. But drugmakers are expecting increased sales in the US. The Times also notes that EU citizens may have greater protection from the seasonal flu than those in the US because the EU uses adjuvanted vaccines. http://www.ft.com/cms/s/c6a7e850-82d6-11df-b7ad-00144feabdc0,Authorised=false.html?_i_location=http%3A%2F%2Fwww.ft.com%2Fcms%2Fs%2F0%2Fc6a7e850-82d6-11df-b7ad-00144feabdc0.html&_i_referer=http%3A%2F%2Fsn129w.snt129.mail.live.com%2Fmail%2FInboxLight.aspx%3FFolderID%3D00000000-0000-0000-0000-000000000001%26InboxSortAscending%3DFalse%26InboxSortBy%3DDate%26n%3D2080073193 More pharmaceutical research updates at http://www.pharm-education.com/2010/07/dengue-returns-to-us-sanofi-sees-phase.html Disclaimer- The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances. Http://www.drshrutibhat.com Expert at leading Pharmaceutical R&D. Translates innovative concepts to PROFITS. YouTube Channel : Http://www.youtube.com/user/ShrutiBhat10 Do you have questions for the author?  Dr.Shruti Bhat, Star formulator and Ace leader within pharmaceutical R&D, a specialist with hiTech formulations and quality-by-design. Shruti brings to you some highlights from current pharma and clinical research news, views and data. Doctors Identify Two Therapies That May Slow Progress Of Diabetic Retinopathy. The Los Angeles Times blog reported that, according to data published June 29 in the New England Journal of Medicine and presented at the American Diabetes Association meeting, "doctors said they have identified two therapies that may slow the progress of" diabetic retinopathy. After examining data on a subset of 2,856 people from the ACCORD study, researchers found that "people with type 2 diabetes who adhere to intensive blood sugar control, compared with standard blood sugar control, have reduced progression of retinopathy. In addition, patients treated with a combination of a cholesterol-lowering statin and fibrate drugs also had a lower rate of progression compared with patients taking statins alone." http://latimesblogs.latimes.com/booster_shots/2010/06/diabetes-retinopathy-glucose-control.html http://content.nejm.org/cgi/content/full/NEJMoa1001288 http://www.nhlbi.nih.gov/health/prof/heart/other/accord/index.htm Weight-Loss Supplement Contains Potentially Dangerous, Undeclared Drug Ingredients, FDA Warns. MedPage Today reported, "The FDA warned customers about several potentially dangerous and undeclared drug ingredients in Que She, a pill sold as ... More at http://www.pharm-education.com/2010/07/eu-approves-chewable-form-of-lipitor.html Disclaimer- The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances. Http://www.drshrutibhat.comExpert at leading Pharmaceutical R&D. Translates innovative concepts to PROFITS. YouTube Channel : Http://www.youtube.com/user/ShrutiBhat10 Do you have questions for the author?  Dr.Shruti Bhat, Star formulator and Ace leader within pharmaceutical R&D. Shruti is a specialist with hiTech formulations and quality-by-design. Shruti brings to you some highlights from current pharma and clinical research news, views and data. The U.S. Food and Drug Administration yesterday announced it has approved the Implantable Miniature Telescope (IMT) to improve vision in some patients with end-stage age-related macular degeneration (AMD). Surgically implanted in one eye, the IMT is a small telescope that replaces the natural lens and provides an image that has been magnified more than two times. AMD, a condition that mainly affects older people, damages the center of the retina (macula) and results in a loss of vision in the center of the visual field. About 8 million people in the United States have AMD and nearly 2 million of them already have significant vision loss, according to the National Eye Institute. AMD can make it difficult or impossible to recognize faces or perform daily tasks such as reading ... Read more at http://www.pharm-education.com/2010/07/fda-approves-first-implantable.html Disclaimer- The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances. Http://www.drshrutibhat.comExpert at leading Pharmaceutical R&D. Translates innovative concepts to PROFITS. YouTube Channel : Http://www.youtube.com/user/ShrutiBhat10 Introducing ! A new blog- Http://www.PharmaceuticalCareerDevelopment.blogspot.com which contains articles on motivation, career counselling and coaching, job search strategies, personal branding etc. especially for pharma professionals.  Dr.Shruti Bhat, Leader Pharmaceutical R&D and Expert in hiTech formulation development for over 35 different therapeutic class of drugs moeities, brings to you some highlights from current pharma and clinical research news, views and data. Resveratrol May Help Prevent Age-Related Deterioration Of Eyesight. Resveratrol, found in particularly high levels in grape skin (and consequently red wine)," may help prevent age-related deterioration of eyesight, according to a study published in the American Journal of Pathology... http://www.telegraph.co.uk/health/healthnews/7851772/Drinking-wine-could-protect-your-eyes.html Pfizer Suspends Clinical Trials Of Tanezumab As Potential Osteoarthritis Treatment. Pfizer Inc. Spokesperson said Wednesday it has suspended clinical trials of its drug tanezumab as a potential osteoarthritis treatment, after some patients' conditions worsened." The drugmaker "said it halted the worldwide program following ,,, http://www.forbes.com/feeds/ap/2010/06/23/business-health-care-us-pfizer-halts-study_7714952.html http://www.bloomberg.com/news/2010-06-23/pfizer-suspends-trial-of-tanezumab-for-osteoarthritis-pain-at-u-s-request.html http://online.wsj.com/article/SB10001424052748703900004575325320800502744.html Glucosamine, Chondroitin Sales Remain Strong Despite Evidence They May Be Ineffective. Despite a 2006 study published in the New England Journal of Medicine that suggested that "for most people, glucosamine and chondroitin do not soothe knee pain much better than ...." SSRI Antidepressant Use Associated With Cataracts. According to a study published online in the journal Ophthalmology, "SSRI antidepressants raise the risk of cataracts by about 15% -- enough to cause 22,000 extra cataract cases in the US each year." After analyzing "data collected from 18,784 cataract patients and 187,840 comparison patients between 1995 and ,,, More at http://www.pharm-education.com/2010/06/resveratrol-seems-to-be-promising-drug.html Disclaimer- The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances. Http://www.drshrutibhat.com Expert at leading Pharmaceutical R&D. Translates innovative concepts to PROFITS. YouTube Channel : Http://www.youtube.com/user/ShrutiBhat10 Introducing ! A new blog- Http://www.PharmaceuticalCareerDevelopment.blogspot.com which contains articles on motivation, career counselling and coaching, job search strategies, personal branding etc. especially for pharma professionals. Do you have questions for the author?  Dr.Shruti Bhat, Leader Pharmaceutical R&D and Expert in hiTech formulation development for over 35 different therapeutic class of drugs moeities, brings to you some highlights from current pharma and clinical research news, views and data. Antiretroviral Therapy Treatment May Reduce Perinatal AIDS Transmission. According to studies published June 17 in the New England Journal of Medicine, "AIDS transmission to babies was blocked in 99 percent of cases when breastfeeding mothers infected with the HIV virus took triple-drug combinations." In fact, one study in Botswana of 730 pregnant women with HIV found that ... Experimental Colon Cancer Treatment Fails To Meet Goal In Midstage Study. A potential colon cancer treatment failed to meet its goal in a midstage study." The research "was conducted by Curis' partner Roche and ... After 12 Months, Aspirin OK Without Plavix For Patients With Stents. Giving aspirin alone to patients who have had stents implanted seems just as good as giving aspirin along with the blood thinner Plavix [clopidogrel]," according to a study presented at the American College of Cardiology annual meeting. Researchers discovered that, ... Investigational Implantable Sensor May Reduce Risk Of Hospitalizations For Heart Failure. A study being called the start of a revolution in the management of heart failure." Among heart failure patients with moderate to severe disease, six months of monitoring with an investigational implantable sensor that measures pulmonary artery pressure was associated with a 30% relative risk reduction in hospitalizations for heart failure," according to ... FDA Seeks More Information On Inhaled Insulin Drug. MannKind Corp.allegedly "failed to win approval from US regulators to market its inhaled insulin drug, Afrezza, for people with diabetes." The FDA "asked for ... Further reading at http://www.pharm-education.com/2010/06/investigational-implantable-sensor-may.html Related links- http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm215515.htm http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm216214.htm http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm216218.htm http://www.medscape.com/viewarticle/723988 http://www.bloomberg.com/apps/news?pid=newsarchive&sid=aTKRE8oVsUVg http://consumer.healthday.com/Article.asp?AID=640176 http://content.nejm.org/cgi/content/full/362/24/2271 http://www.medpagetoday.com/HIVAIDS/HIVAIDS/20717 http://www.bloomberg.com/apps/news?pid=20601202&sid=aJxiB1BIwgUM http://www.forbes.com/feeds/ap/2010/06/16/business-health-care-us-curis-mover_7694092.html http://www.reuters.com/article/idUSSGE65F0G020100616 Disclaimer- The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances. Http://www.drshrutibhat.com Expert at leading Pharmaceutical R&D. Translates innovative concepts to PROFITS. YouTube Channel : Http://www.youtube.com/user/ShrutiBhat10 Check out a new blog exclusive for pharma professionals Http://www.PharmaceuticalCareerDevelopment.blogspot.comDo you have questions for the author?  Dr.Shruti Bhat, Leader Pharmaceutical R&D and Expert in hiTech formulation development for over 35 different therapeutic class of drugs moeities, brings to you some highlights from current pharma and clinical research news, views and data. Presented below are updates in Pharmaceutical and clinical research- Teva Announces Positive Results from a Study Assessing a New Formulation of Copaxone(R). Significantly less pain and fewer injection site reactions were reported by patients receiving the new lower volume injection. Teva Pharmaceutical Industries Ltd. announced positive results from a study assessing a new lower-volume injection of Copaxone(R) (glatiramer acetate) containing the currently approved dose in half the injection volume. The SONG study ('Study of New Glatiramer Acetate Formulation') explored the safety and tolerability of... http://www.marketwatch.com/story/teva-announces-positive-results-from-a-study-assessing-a-new-formulation-of-copaxoner-2010-06-04?reflink=MW_news_stmp Starpharma Plans Effectiveness Studies On Herpes-Killing Gel For Women. Bloomberg News reported, "The world's first herpes-killing vaginal gel may go on sale within two years, said its developer Starpharma Holdings Ltd., which plans to start patient studies on its effectiveness." Starpharma CEO Jackie Fairley said ... http://www.bloomberg.com/apps/news?pid=20601202&sid=aqEEau5hBC6Q Bevacizumab May Improve Some Outcomes In Advanced Gastric Cancers. MedPage Today reported that "bevacizumab (Avastin) may improve some outcomes in advanced gastric cancers, but it did not benefit overall survival, according to ... http://www.medpagetoday.com/MeetingCoverage/ASCO/20582 Erlotinib May Prolong Survival In Older Women With Advanced Non-Small Cell Lung Cancer. MedPage Today reported that "the targeted agent erlotinib (Tarceva) prolonged survival by 26% in older women with advanced non-small cell lung cancer, but did not benefit men with the disease," according to research presented ... http://www.medpagetoday.com/MeetingCoverage/ASCO/20581 Mapatumumab Fails In Midstage Study. "Human Genome Sciences's potential cancer drug mapatumumab failed in a midstage study. The company found "no difference in disease response ... http://www.forbes.com/feeds/ap/2010/06/09/business-health-care-us-human-genome-sciences-study_7672784.html http://www.reuters.com/article/idUSSGE6580FL20100609 Rosiglitazone, Metformin Low-Dose Combination May Reduce Progression To Type 2 Diabetes. The Los Angeles Times reported, "A combination of low doses of the diabetes drugs Avandia [rosiglitazone] and metformin can reduce the progression to type 2 diabetes by two-thirds in people who are at high risk of developing the disease," according to a study published online in The Lancet. In fact, "the benefit is greater than with either of the drugs used alone, and ... More at http://www.pharm-education.com/2010/06/rosiglitazone-metformin-low-dose.html Http://www.drshrutibhat.comExpert at leading Pharmaceutical R&D. Translates innovative concepts to PROFITS. YouTube Channel : Http://www.youtube.com/user/ShrutiBhat10 Shruti has initiated a new blog Http://www.PharmaceuticalCareerDevelopment.blogspot.com which contains articles on motivation, career counselling and coaching, job search strategies, personal branding etc. especially for pharma professionals. Do you have questions for the author? | AuthorShruti is a visionary leader,a result-oriented professional and a pharmaceutical scientist targeting path- breaking research and technologies of future.  ArchivesAugust 2010 CategoriesAll |
RSS Feed